These results provide arguments to consider harnessing NK‐cell‐mediated cytotoxicity to improve the success of therapies in melanoma patients harboring mutant BRAF, and in particular those who have become refractory to BRAFi treatment. The gene discussed is BRAF; the disease is melanoma.